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Heart Disease is the number one cause of death in the United States and affects many 
individuals on a daily basis. The purpose of this research was to explore possible tissue 
regeneration therapies that aim to improve and recover function of damaged myocardial tissue 
commonly seen as a side-effect of chronic heart disease. Cardiac tissue engineering using 
induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) is a relatively new method 
that involves dedifferentiating cells from any tissue of the host into pluripotent stem cells. 
These cells are then guided to be differentiated into functioning myocardial cells that can be 
used to repair damaged tissue and restore cardiac function to affected areas. The process and 






Heart Disease is the number one cause of death in the United States, accounting for 
approximately 1 in 4 deaths, and affects many individuals on a daily basis1. A common 
definition for cardiovascular or heart disease is some condition affecting either the blood 
vessels, tissue, or valves of the heart that often leads to a heart attack or stroke. Some of the 
most common types of heart disease include but are not limited to coronary heart disease, 
atrial fibrillation, heart valve disease, congenital heart disease, pericarditis, and heart murmurs. 
Currently one of the only effective long-term treatment options to recover the damaged 
cardiac tissue associated with chronic heart disease is a heart transplantation2. However, with a 
critical shortage of donor hearts available and no affordable option for long distance 
transportation, this option can be hard to rely on. What is needed now is a treatment that aims 
to replace or regenerate infarcted myocardial tissue. A heart infarction occurs whenever there 
is an area of cardiac tissue that obtains an insufficient amount of blood, commonly due to 
events such as a thrombus or embolus, and likely causes local tissue death3. One upcoming way 
to possibly replace or regenerate the diseased or damaged tissue is cardiac tissue engineering 
in vitro using induced pluripotent stem cells (iPSCs).  
Stem cells have an unlimited capacity for self-renewal and give rise to cells that will 
undergo terminal differentiation4. They can be found in most tissues in the human body and aid 
in regeneration of that tissue’s specific functioning cells. For example, hemopoietic stem cells 
have the ability to terminally differentiate and replace the many different types of cells in the 
blood. Similarly, the stem cells in the intestine differentiate to renew the lining of the GI tract 
and the stem cells in the basal layer of the epidermis differentiate to replace the dermal cells of 
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the skin. On the other hand, there are some stem cells, such as the ones found in the embryo 
that possess the ability to produce each and every tissue cell in the body5. These are considered 
pluripotent. Pluripotent stem cells are one step above tissue stem cells in that they give rise to 
the tissue-specific stem cells such as the epithelial and dermal cells described earlier.  
Induction of these pluripotent stem cells and the ability to use them to recover heart 
tissue is the topic of this paper. Induced pluripotent stem cells (iPSCs) are obtained by taking a 
terminally differentiated cell and de-differentiating it, thus stripping it down of all of the 
qualities that make it that kind of cell. For example, one has the ability to take dermal cells, de-
differentiate and reprogram them until they become “embryonic like” pluripotent stem cells, 
thus now having induced pluripotent stem cells. These new induced pluripotent cells now have 
the potential to differentiate into any tissue5. They can be guided using growth factors or 
exposing the cell to a certain environment to become any tissue including a cardiomyocyte 
which is the main functional cell in heart tissue. The once dermal cell can thus be made into a 
cardiomyocyte. This process can be used for reproductive cloning6 but can also be used for 
therapeutic purposes because of their patient-specific capacity. This paper will be focusing on 









Successful induction of iPSC from adult human fibroblasts was obtained by the 
Yamanaka lab at Koyota University7. The protocol for this process involves introducing four 
transcription factors, Oct3/4, Sox2, Klf4, and c-Myc to human dermal fibroblasts derived from 
the facial dermis of a 36-year-old Caucasian male. After 30 days of culturing, some cells showed 
human embryonic stem cell-like (hESC) qualities. The cells resembled hESCs in physical 
appearance by having a large nuclei and scant cytoplasm. Figure 1 displayed below contains 
images and descriptions from the study. Image C demonstrates what a typical non-embryonic 
cell looks like. This would an example of a terminally differentiated cell such as the dermal cell 
used in this study. Image D is what a typical hESC looks like and images E and F are the 
successfully de-differentiated dermal cells into induced pluripotent stem cells or iPSCs. 
Comparison of these images shows the similar morphology of the iPSCs to a typical pluripotent 
hESC. 
 
Takahashi et al. (2007) 
 
Figure 1.  
Induction of iPS Cells from Adult HDF 
(A) Time schedule of iPS cell generation. 
(B) Morphology of HDF. 
(C) Typical image of non-ES cell-like 
colony. 
(D) Typical image of hES cell-like colony. 
(E) Morphology of established iPS cell 
line at passage number 6 (clone 201B7). 
(F) Image of iPS cells with high 
magnification. 
(G) Spontaneously differentiated cells in 





 In addition to sharing similar morphology, the iPSCs expressed hESC-specific surface 
antigens SSEA-3, SSEA-4, tumor-related antigens (TRA)-1-60, TRA-1-81, TRA-2-49/6E, and 
NANOG protein. Wetstern blotting also showed evidence of dedifferentiation when it revealed 
protein levels of OCT3/4, SOX2, NANOG, SALL4, E-CADHERIN, and hTERT that were similar to 
hESCs. Lastly, the dedifferentiated cells showed high telomerase activity with a calculated 
doubling times of 46.9± 12.4, 47.7± 6.6, and 43.2 ± 11.5 hours. These times are equivalent to 
earlier reported population doubling times of hESCs. Because of similarity in morphology, 
surface antigens, gene expression, and telomerase activity, the adult human fibroblasts were 
determined to be dedifferentiated into iPSCs that mimicked the function of hESCs.   
 
Differentiation   
 After dedifferentiating the iPSCs, they now have the potential to be differentiated into 
one of many lineages of cell types. This paper is interested in the differentiation of the iPSCs 
into functional cardiomyocytes. There are several methods of differentiating iPSCs into 
functioning cardiomyocytes, three of which being the embryoid body method8, the matrix 
sandwich method9 and the small molecule method10.  
 The embryoid body (EB) method is one of the first methods of differentiating iPSCs into 
cardiomyocytes and is primarily based on giving cardiac specific growth factors to the 
pluripotent cells and allowing them to join together to make a three dimensional body8. The 
iPSCs were introduced and cultured with differentiation medium (EB20) that consisted of 80% 
DMEM/F12, 0.1 mmol/L nonessential amino acids, 1mmol/L l-glutamine, 0.1 mmol/L β-
mercaptoethanol, and 20% FBS that was pretested for cardiac differentiation to create three 
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dimensional embryonic bodies (EBs). This was used to initiate cardiac differentiation from the 
human iPSCs. The EBs were cultured with their medium changed regularly. In as little as 10 
days, some of the EBs had recorded contraction rates which suggested differentiation to a 
functioning cardiomyocyte. The contraction forces were by no means comparable to the force 
generated by an original cardiomyocyte but the point of this observation is that the EBs have 
started to differentiate into a beating cardiomyocyte. Labs have started to develop new 
methods for maturation11 of rat and human engineered heart tissue by chronic electrical 
stimulation13, by cyclic stretch14, or using vascular loading and vascular co-culture15.   
 Gene expression patterns of these EBs were tested on day 60 when cardiogenesis reached a 
stable plateau. As seen in Figure 2A taken from this study, multiple cardiac genes were tested 
for expression using a quantitative RT-PCR machine in the iPSCs and EBs: transcription factor 
Nkx2.5 (NKX2-5), several myofilament protein genes including cardiac troponin T (TNNT2), α-
myosin heavy chain (MYH6), α-actinin (ACTN2), myosin light chain 2 atrial isoform (MYL7), 
myosin light chain 2 ventricular isoform (MYL2), atrial natriuretic factor (HPPA), and 
phospholamban (PLN). At day 60, the undifferentiated iPSCs showed low expression of cardiac 
genes, shown with a dull mark, while the cardiomyocyte differentiated EBs showed a significant 
upregulation of the full range of cardiac genes, shown with a bight mark. Also, Figures 2B and 
2C show that the pluripotent genes OCT4 and NANOG were downregulated in the 
differentiated cardiomyocyte EBs which suggests that the embryoid body method of 





 Zhang et al. (2009) 
The matrix sandwich method is another method of differentiating pluripotent stem cells 
into cardiomyocytes that involves a more effective protocol by using extracellular matrix (ECM) 
in combination with growth factors known to promote cardiogenesis9. The process reported by 
a lab at the University of Minnesota used pluripotent stem cells cultured as a monolayer on 
Matrigel, a layer of ECM preparation, and overlayed with another layer of Matrigel to create a 
“matrix sandwich”. This promoted an epithelial- to –mesenchymal transition as seen in 
gastrulation with the generation of N-cadherin mesenchymal cells. Figure 3 taken from this 
study displays below the addition of the N-cadherin mesenchymal cells seen in this method. 
The addition of growth factors known for cardiogenesis (Activin A, BMP4, and bFGF) to the 
matrix sandwich generated cardiomyocytes with high purity and yield that formed contracting 
sheets by day 15. Using RT-QPCR results, the contracting cells showed significant upregulation 
of early mesoderm genes T and MESP1, cardiac transcription factors of GATA4, ISL1 and NKX2-
5, and cardiac myofilament proteins TNNT2, TNNI3, MYL7, and MYL2. In pluripotent genes 
Figure 2: Cardiac and Pluripotency 
Gene Expression in Cardiomyocytes 
Derived from iPS and ES Cells. (A) 
RT-PCR analyses of pluripotency 
genes, OCT4 and NANOG, and 
cardiac genes in undifferentiated iPS 
and ES cells, day 60 EBs, and adult 
left ventricular myocardium (LV). (B 
and C) Quantitative RT-PCR 
analyses of total OCT4 (B) and 
NANOG (C) expression in 
undifferentiated iPS and ES cells 
compared to differentiated 
contracting areas from day 60 EBs. 
Error bars represent SEM (n=3), *** 
indicate P < 0.001 comparing gene 
expression in undifferentiated cells 




OCT4 and NANOG, the contracting cells showed significant downregulation which suggests that 




Zhang et al. (2012) 
 
The third method of differentiation of iPSCs into functioning cardiomyocytes is 
accomplished serum-free by modulating Wnt/β- catenin signaling10. This method involves 
culturing a monolayer of iPSCs with the addition of growth factors important in cardiovascular 
development such as fibroblast growth factor 2 (FGF2), transforming growth factor β (TGFβ), 
superfamily growth factors Activin A and BMP4, and vascular endothelial growth factor (VEGF). 
Appropriate application of Gsk3 inhibitor followed by β- catenin shRNA or a chemical Wnt 
inhibitor provides the opportunity of producing a high yield of virtually pure functional 
cardiomyocytes from human iPSCs without cell sorting or selection. At day 4 of culture, gene 
expression of cardiac transcription factors NKX2.5 and ISL1 can be detected with cardiac 
proteins detected at day 5. Cardiac Troponin T (cTnT) can be detected as soon as day 8 of 
Figure 3 
(A) Confocal imaging of iPSCs (DF19-9-11T) seeded as 
single cells on Matrigel coated surface and propagated 
in mTeSR1 for 4 days without Matrigel overlay (Control) 
or with a Matrigel overlay (Matrix Sandwich) for the last 
24 hours. 3D reconstructed z-series of images labeled 
with an antibody to laminin, fluorescent-conjugated 
WGA for glycoproteins, and DAPI for nuclei. Scale bars 
are 20 μm. (B) Electron micrographs of control cultures 
demonstrate confluent monolayers compared to matrix 
sandwich cultures which are multilayered with an upper 
epithelial layer and mesenchymal cells below. Arrows 
indicate microvilli. Scale bars are 5 μm. (C) 
Epifluorescence images of control and matrix sandwich 
cell culture 24 hours after Matrigel overlay 
immunolabeled with E-cadherin and N-cadherin 
antibodies. Scale bars are 100 μm. (D) Comparison of 
average number of N-cadherin+ foci (per 1.8 cm2 
surface area) in control and matrix sandwich cell 
cultures (DF19-9-11T). Error bars represent SEM, N=3. 
Data were compared using Student’s t-test with ** 




culture. The formation of differentiated functional cardiomyocytes can be established by visual 
observation of contracting regions, with the first beating observed between days 8 and 10.  
 
Comparison to Embryonic Stem Cells  
Mesenchymal stem cells16, cardiac progenitor cells12, cardiosphere-derived cells17, and 
human embryonic stem cells (hESCs)15, 18,14 have all been administered as a therapy for 
reducing myocardial infarction damage and has shown improvement in cardiac tissue function. 
hESCs are stem cells derived from an embryonic origin and are thus pluripotent in nature. There 
are similarities in the function of hESC- derived and iPSC- derived cardiomyocytes10 because 
both of the cells are pluripotent and have the potential to differentiate into one of the many 
cell lineages in the human body. The difference between the two comes from where the 
original cell is derived from. As stated before, iPSCs are cells taken from anywhere in the body 
and are dedifferentiated to an induced pluripotent state to produce functional 
cardiomyocytes22. On the other hand, hESCs are already pluripotent because they are 
embryonic and thus already have the potential for differentiation into cardiomyocytes. Because 
of the associated use of human embryos for regenerative therapy, hESCs are linked to major 
ethical concerns and are likely to be overlooked. hESCs are also not patient-specific in 
comparison to iPSCs that use cells from the patient themselves to regenerate a specific type of 
tissue. An individual that used regenerated tissue derived from hESCs would risk an adverse 
immune/inflammatory reaction and would likely have to take immunosuppressants for the 
remainder of their lifetime. Despite the ethical and immune problems, hESCs are very similar in 
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function to iPSCs when used as a regenerative therapy and are useful in determining 
effectiveness of iPSCs for therapy.    
A lab at Duke University created a tissue-engineered cardiac patch (Figure 4A) made 
from hESC- derived cardiomyocytes to test its functional maturity for possible future use in 
regenerative cardiac tissue therapy18. After 20-30 days of differentiation, hESC- derived 
cardiomyocyte populations were used to make 3D cardiac patches with elliptical pores to 
facilitate nutrient transport and enable properly aligned cardiac tissue (Figure 4B and 4C). Using 
the immunostaining process for cardiac markers, the cells revealed aligned cardiomyocytes 
exhibiting cross-striated patterns of troponin T (cTNT), myosin heavy chain (MHC) and α- actinin 
(SAA), which suggests well-developed sarcomeric structures (Figure 4D and 4E). 
Immunostaining also for N-cadherin (Figure 4F) and connexin-43 (Cx43) demonstrated the 
presence of intercellular gap and adherens junctions, indicating functional electromechanical 
coupling between cardiomyocytes. Using quantitative RT-PCR data, it was shown that 
expression of pluripotency specific genes OCT4 and NANOG were significantly downregulated 
during the differentiation process and nearly disappeared in the cardiac patches. On the other 
hand, early cardiac markers ISL1 and GATA4 increased with cardiac differentiation suggesting 
complete cardiac differentiation. More evidence of cardiac function came from optical mapping 
of transmembrane potentials which revealed continuous action potential propagation in the 
cardiac patches. Because of evidence revealing successful electromechanical coupling, 
downregulation of pluripotent genes with upregulation of cardiac-specific genes, and action 
potential propagation among the hESC- derived cardiomyocytes, it can be suggested that hESCs 
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are successful in creating mature functioning cardiomyocytes that could possibly be used in 
cardiac tissue regenerative therapies. 
            
Zhang et al. (2013) 
 
Administered IPSCs to cardiac tissue 
 Because of the high proliferation rate of iPSCs, direct injection into damaged tissue that 
needs to be repaired could cause tumor formation. To avoid this issue, many protocols 
involving administration of iPSC- derived cardiomyocytes (iPSC-CMs) onto damaged or infarcted 
heart tissue form the cells into a cardiac patch.   
 One lab at the University of Minnesota used tissue-engineered cardiac patches as a 
possible method to deliver cardiomyocytes to injured myocardium to enhance the ability of 
cells to limit remodeling as well as improve contractility and function after infraction19. This lab 
hypothesized that cardiac patches made from human induced pluripotent stem cell- derived 
cardiomyocytes (hiPSC-CMs) would decrease the infarction area and increase fractional 
shortening (contractility) of affected hearts in a span of 4 weeks. hiPSC-CMs were prepared, 
and cultured to be harvested in 10 days. Aligned cardiac patches were created by combining 
Figure 4 
Structural properties of human cardiac tissue patches 
A) Representative 2-week old cardiac tissue patch 
anchored within a Velcro frame. B-C) Staggered elliptical 
pores within the patch (B) are surrounded by densely 
packed and aligned cells (C). D) hESC-CMs in 2-week 
old cardiac tissue patches are aligned and show cross-
striated patterning of cardiac Troponin T (cTnT). 
Fibroblasts positive for vimentin (Vim) are interspersed 
among hESC-CMs. E) hESC-CMs also exhibit cross-
striated pattern of myosin heavy chain (MHC) and 
sarcomeric α-actinin (SAA). F) Cardiac patches show 
evidence of mechanical coupling (N-cadherin) between 
hESC-CMs as well as presence of smooth muscle cells 





the hiPSC-CMs and non-cardiac pericytes on a fibrin gel (CM+PS patch). Fibrin gels are often 
used as a biological scaffold because the cells are likely to remodel the fibrin matrix and replace 
it with their own extracellular matrix (ECM) in comparison to other collagen gels20. Rats were 
anesthetized and received a limited left lateral thoracotomy to expose the heart. An induced 
myocardial infarction was achieved by permanently ligating the left anterior descending 
coronary artery with a suture. The cardiac patch was applied to the damaged area by applying 
thin strips parallel to each other and securing with sutures. Cardiac function was assessed via 
echocardiograph, and multiple fluorescent images.  
Echocardiography conducted from week 1 to week 4 postoperatively determined that 
all groups displayed a reduction in both the left ventricular ejection fraction (LVEF) and 
fractional shortening (LVFS) relative to baseline. However, the degree of reduction was less in 
the rats that contained the CM+PS cardiac pads in comparison to the rats that were not given a 
cardiac patch. The rats that received CM+PS patches also showed smaller left ventricular inner 
diameter in systole compared to the non-treatment group. In addition to a smaller diameter, 
the CM+PS patches showed the most significant decrease in infarct scar tissue, as shown below 
in Figure 5A and 5B from the study. New cardiomyocyte formation was observed from the 
patch which was shown by the increased angiogenesis of the area as well as proof of 
collagenous extra cellular matrix (ECM) formation and gap junctions between adjacent 
cardiomyocytes.  
The results from this lab suggest that an engineered cardiac patch using hiPSC-CMs and 
PSs trapped in a fibrin gel is a successful therapy to improve function of damaged heart tissue. 
They found that when applied to infracted rat myocardium, the aligned, force-generating patch 
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remained viable and the CM proliferated. The patch improved cardiac function and reduced 
infarction size after the 4 week period.  
 
  
Wendel et al. (2015) 
 
Another lab using cardiac patches that show that engraftment of a mixture of hiPSC-CM, 
endothelial cells, and smooth muscle cells in combination with a IGF-1-fibrin patch into a 
porcine model of myocardial infraction improved heart function and metabolism without 
producing arrhythmias21.  
   
Derivation of Undifferentiated Cells  
 Jianyi Zhang’s lab at the University of Minnesota realized that iPSCs could be 
differentiated into unlimited lineages of cell types but questioned whether the origin of the 
dedifferentiated cell mattered in terms of efficiency of the differentiation process, as well as 
the functionality of the final outcome22. This lab believed that the function of the iPS cell- 
derived cells may be influenced by epigenetic factors that the cells retained from their origin 
Figure 5.  
Infarct size and left ventricular (LV) wall thickness. (A): 
Masson’s trichrome images of MI-only, CM+PC, and PC 
patch hearts, showing representative infarct sizes (blue) 
and left ventricular anterior wall thickness. CM+PC patch 
recipient hearts had smaller infarct sizes (B) than did the 
infarct-only control rats, and no reduction in infarct size 
was seen in the PC patch recipient hearts. No reduction in 
LV anterior wall thickness (C) was observed with either 
treatment group. Patch not easily visualized in sections. 
Asterisk indicates comparison with MI-only, number sign 
indicates comparison with CM+PC patch, and dollar sign 
indicates comparison with PC patch. Abbreviations: CM, 
cardiomyocyte; LV, left ventricular; MI, myocardial 




and thus chose to dedifferentiate cardiac-lineage cells, rather than (for example) dermal 
fibroblasts, into human cardiac induced- pluripotent stem cell cardiomyocytes (hciPSC-CMs). 
This study was published in 2015 and reported the first experiments to use iPSCs that have 
been engineered from cardiac fibroblasts. The fibroblasts used in this study were obtained from 
the left atrial appendage of three patients that underwent open heart surgery. The tissue was 
dissociated and single cardiac fibroblasts were collected and dedifferentiated using the 
CytoTune™-iPS Reprogramming Kit (invitrogen). Once the cells were examined for 
morphological similarities to embryonic stem cells and tested for expression of pluripotency 
transcription factors, the hiPSCs were differentiated into cardiomyocytes by the Matrigel 
sandwich method and treated with different mediums and transcription factors such as Activin 
A, BMP4, bFGF, RPMI and B27. Differentiation was successful as the pluripotency markers Oct4, 
Sox2, and Nanog were significantly reduced while expression of early mesodermal and cardiac 
mesodermal (Mesp1, Nkx2.5, Gata4, Mef2C, and Tbx5) markers had significantly increased. The 
now induced cardiomyocytes began beating on approximately day 8 of the process and cardiac 
patches were made by suspending sheets of cardiomyocytes that have been beating for 10 days 
in fibrinogen.   
Myocardial infarction (MI) was surgically induced in 12 week old immunodeficient mice 
by permanently litigating the left-anterior descending coronary artery with a surgical silk 
suture. The surviving mice were separated into two groups: ones that were treated with the 
hiPSC-CM patch and the others that were treated with just a fibrinogen patch. The chest of the 
mice were closed, the mice were allowed to recover and an echocardiography and staining 
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procedures were used four weeks after the MI and cell transplantation to evaluated cardiac 
function.     
iPSC-CMs were also derived from different tissues (hUCBiPSC: from human umbilical 
cord blood mononuclear cell, and hdiPSC: from human dermal fibroblasts) as a way to test the 
differences in function of induced cardiomyocytes that started from different origins in 
comparison to induced cardiomyocytes that originated at heart tissue to start with. Results 
show that hciPSC-CMs have a more cardiac-like Ca2+ handling profile compared to CMs derived 
from hUCBiPSCs or hdiPSCs.  
Overall, this experiment showed that human iPSCs can be successfully generated from 
cardiac fibroblasts and the hciPSCs can be differentiated into CMs with >92% efficiency. It is 
thought that the greater than 92% differentiation efficiency likely reflects the epigenetic 
memory of the cardiac origin of the fibroblast. The mice that received the CM-sheet 
transplantation showed significantly improved left ventricular contractile function as well as a 
reduction in the process of apoptosis and increased vascular formation in comparison to the 
mice that were treated with just the fibrinogen patch. With the help of the data from this 
experiment, the potential of hciPSC-CM sheet transplantation for treatment of acute 
myocardial infarction is very promising. 
    
Maturation of iPSC-CMs for higher function  
Higher functioning iPSC-CMs could be reached with the proper alignment23 of the 
engineered cells onto the damaged heart tissue. Native myocardium are able to function in-
sync and follow a specific rhythm because of their extensive mechanical and electrical 
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alignment. This alignment produces a property of anisotropy: a property of being directionally 
dependent, as opposed to isotropy, which implies identical properties in all directions. This 
electromechanical anisotropy is due partly by the aligned myocytes and matrix fibers but most 
of the synchronal properties of cardiac tissue is due to gap junctions found between the 
functioning cells. Gap junctions are specialized transmembrane proteins that allow the easy 
flow of ions between adjacent myocardial cells which in turn, allows synchronized contraction 
of the heart muscle that functions to propel blood into the pulmonary and systemic circuits. A 
lab at the University of Minnesota aimed to evaluate the impact of cell and matrix alignment on 
tissue function in engineered myocardium. They entrapped neonatal rat cardiac cells in a fibrin 
gel and by appropriately constraining the cell-induced fibrin gel contraction, were able to align 
the fibrin fibers which aligned the cells in contact with the fibrin. The result was and aligned 
myocardial equivalent with cells producing their own extracellular matrix. Along with the 
aligned construct, the lab also created an isotropic construct in order to study the 




         
Black et al. (2009) 
 
Figure 6 shows the aligned (A) and isotropic construct (B) after two weeks of culture. 
Figure 6A shows that that aligned construct contracted to a thin ring while the isotropic 
construct remained flat. 6C and 6D show, with polarized light imaging, the matrix alignment, or 
lack thereof. The aligned construct in 6C shows high alignment in the circumferential direction 
while the isotropic construct in 6D shows no preferential alignment.  
 The passive mechanical properties of each construct was measured using a strain-to-
failure test and the twitch force was recorded by stimulating the cells with an electrical 
stimulus. In both tests, the aligned construct showed a higher functioning cell function. In 
comparison to the isotropic construct, the aligned group had a greater ultimate tensile strength 
as well as maximum strength achieved before failure. The aligned group also performed better 
in the twitch force tests (FIG. 7), with a 181% increase in twitch force associated with electrical 
pacing, in comparison to the isotropic group.    
FIG. 6. 
Images of isotropic (A) and aligned (B) constructs 
after 14 days in culture with corresponding 
polarized light alignment images (C, D). In (C, D) 
the constructs have been cut axially and splayed 
flat. The grayscale values represent the 
birefringence of the tissue, a measure of the 
strength of alignment, and the lines (black in C, 
white in D) indicate the local average direction of 
alignment in the tissue. Note that the aligned 
construct (D) is highly aligned in the 
circumferential (vertical) direction, while the 
isotropic construct (C) does not possess 
alignment. Cellular alignment, measured via 
staining of filamentous actin, matched matrix 
alignment assessed via polarized light for both 




      
 Black et al. (2009) 
The lab’s hypothesis for the improvement of function of aligned construct compared to 
isotropic construct was that the aligned cells were able to form gap junctions between their 
cells and, thus, increased their electromechanical function. To test this hypothesis, the lab used 
Western Blot Analysis to test for Connexin 43 expression, a common protein seen in gap 
junction formation. As expected, the aligned construct showed a significantly greater 
expression of Connexin 43 (FIG. 8) in comparison to the isotropic construct and, therefore, 
suggests a greater number of gap junctions present. The results of this data suggest that the 
proper alignment of engineered myocardium is imperative to the overall functionality and 
strength of the resulting tissue.   
FIG. 7. 
Representative force 
traces during 1 Hz pacing 
versus time plots for an 
aligned (A) and an 
isotropic (B) construct. (C) 
Pooled twitch force data 
for 14-day-old aligned 
(left) and isotropic (right) 
constructs at 10 mN 
preload during 1 Hz 
pacing. *p < 0.05 (n = 14 





Black et al. (2009) 
Experiment Outline 
There has been evidence suggesting the improvement of myocardial tissue following a 
traumatic heart injury using cardiac patches made from both induced pluripotent stem cell 
derived cardiomyocytes (iPSC-CMs) as well as cardiomyocytes derived from embryonic stem 
cells (ESC-CMs). Tissue regeneration therapies are a common way of repairing and regenerating 
heart tissue that had been damaged and caused some degree of heart infarction. Although the 
process of obtaining ESC-CMs is somewhat simpler than deriving iPSC-CMs, more individuals 
tend to choose iPSC-CMs for a few good reasons. First of all, when using iPSC-CMs, there is 
limited worry for tissue rejection from the damaged tissue. This is because the cells used in 
iPSC-CMs originated from the host’s own tissue, saving the individual from taking a lifetime of 
immunosuppressants potentially needed if foreign ESC-CM’s were used instead. Second, using 
ESC-CMs involves using embryonic cells which could initiate major ethical concerns. Since iPSC-
CMs are derived from the host’s own tissue, there is limited ethical conflicts and is considered 
the better option.  
FIG. 8. 
(A) Representative Western 
blots for connexin 43 (Cx43), 
connexin 43 phosphorylated at 
serine 368 (pCx43s368), 
calsequestrin 2 (Csq2), and β-
actin for two aligned (A1, A2) and 
two isotropic (I1, I2) constructs. 
(B) The ratio of pCx43s368 
expression to Cx43 expression 
for aligned and isotropic 
constructs. (C) The ratio of Cx43 
to Csq2 for aligned and isotropic 
constructs. (D) The ratio of 
pCx43s368 expression to Csq2 
expression for aligned and 
isotropic constructs. *p < 0.05 




Although there are some good reasons that iPSC-CMs should be used in myocardial 
tissue regeneration compared to ESC-CMs, there doesn’t seem to be any evidence as to what 
process functionally performs better when repairing heart infarctions. My question that I would 
like to further explore is if there is a significant difference between using iPSC-CMs or ESC-CMs 
for heart regenerative therapy after a heart infarction. Both options are cardiomyocytes 
derived from a stem cell in a pluripotent state, the difference between them comes from how 
the cell obtained its pluripotency. ESC-CMs are naturally pluripotent as they originated from 
embryonic stem cells, whereas iPSC-CMs were induced to become pluripotent from introducing 
specific transcription factors OCT3/4, Sox2, Klf4, and C-Myc to any of the host’s tissues. Since 
both ESC-CMs and iPSC-CMs were originally pluripotent and were differentiated to become 
functional cardiomyocytes, I would hypothesize that there would be no significant difference 
between the function of either of them when used to repair a heart infarction.  
I would use rat models for this experiment and simulate tissue damage of the heart by 
inflicting a heart infarction by suturing the left anterior descending coronary artery closed. This 
process will decrease blood flow to the left ventricle causing a section of the myocardial tissue 
to become damaged and inhibit function. Using the matrix sandwich method, as explained 
earlier, the pluripotent cells will be differentiated and two types of cardiac patches would be 
made: One using iPSC-CMs and the other using ESC-CMs. The matrix sandwich method involves 
introducing the pluripotent cells to extracellular matrix (ECM) in combination with specific 
growth factors known to promote cardiogenesis such as Activin A, BMP4, and bFGF. Once the 
cardiomyocytes have been differentiated, they will be combined on a fibrin gel to create a 
“cardiac patch” to be placed and aligned directly onto the damaged heart tissue. One group of 
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rats will be administered the iPSC-CM cardiac patch, while another group will be given the ESC-
CM cardiac patch. There will also be another group of rats that undergo the process of the 
heart infarction but will be given nothing to regenerate the tissue. This group will serve as a 
control and will be the basis for which the variable groups will be functionally compared.  
To gather any conclusion to which there is any significant difference between the 
function of the pluripotent cells in repair and regeneration of cardiac tissue, much data has to 
be collected. In this experiment, I will test the function of the left ventricle using 
echocardiography and collecting data related to the left ventricular ejection fraction (LVEF), left 
ventricular fractional shortening (LVFS), and left ventricular inner diameter (LVID) in systole. In 
most instances, a transthoracic echocardiogram (TTE) is used to best see the heart how it is 
functioning. This process is safer than an x-ray because there is no threat of radiation and it also 
produces a clearer picture. An instrument called a transducer is placed on various locations on 
the chest and upper abdomen aimed towards the heart. The transducer emits high frequency 
sound waves, picks up the echo of the sound waves and transmits them into electrical impulses. 
The electrocardiogram machine takes the electrical impulse information and turns it into 2D or 
3D moving pictures of the heart (still pictures can also be taken). If the the patients lungs, ribs, 
or body tissue is blocking the echo from creating a clear picture, often a liquid contrast can be 
administered intravenously to better see the inside of the heart. The TTE echocardiogram 
would be process to measure the ventricular wall size but a different echocardiogram, Doppler 
echocardiogram, is needed to record the motion of blood moving through the veins and to 
record data related to the LVEF and LVFS. The movement of blood reflects sound waves to a 
transducer and an ultrasound computer is able to read the data. The computer can measure 
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direction and speed of the blood flowing through the heart and blood vessels. This is how the 
ejection fraction and fractional shortening can be measured in the hearts of rats containing 
either the iPSC-CM or ESC-CM cardiac patch.  
 I will also gather data on the infarct size using percentage of scar tissue. Using multiple 
staining techniques, I will also be able to test the functionality of environment the cardiac patch 
has made. For example, using trichrome- stained sections, the amount of collagenous matrix 
can be detected, as well as the amount of gap junction protein Connexin 43 that is present. 
Production of collagenous matrix and Connexin 43 is a direct indicator to as how well the 
derived cardiomyocytes are functioning as normal cardiomyocytes. IB4 staining is another 
important process that can detect the presence of angiogenesis, or blood vessel formation. It 
can also detect the Ki-67 protein that is present in proliferating tissue. The presence of 
angiogenesis and Ki-67 protein is evidence that suggests that the cardiomyocytes are growing 
and interacting with its surrounding cardiac tissue.  
Statistical analysis would need to be performed on the data that is recorded in order to 
determine statistical significance between the two variable groups. If there is a slight difference 
in values of data from the ESC-CM and iPSC-CM cardiac patch group but not enough to be 
statistically significant, one could not reject the null hypothesis and the two groups would be 
considered equal. On the other hand, if one group showed statistical significance from the 
other, the null hypothesis would be rejected and the two groups would significantly different. 
This would indicate that there is a superior pluripotent cell that improves functionality of 
cardiac tissue after a heart infarction.       
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Cardiac tissue engineering is a promising field that aims to one day reduce the impact of 
cardiac tissue damage in individuals suffering from chronic heart disease. With the availability 
of donor hearts so low, researchers need a new method of therapy to replace and/or repair 
damaged myocardial tissue. Given the ability of iPSCs to supply large quantities of patient-
specific functional cardiomyocytes for cardiac repair without the risk of immune rejection, 
tissue engineering using iPSCs proves to be one of the most innovative and efficient forms of 
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